IL255738A - A new crystalline form of lenbatinib mesylate and a process for its preparation - Google Patents

A new crystalline form of lenbatinib mesylate and a process for its preparation

Info

Publication number
IL255738A
IL255738A IL255738A IL25573817A IL255738A IL 255738 A IL255738 A IL 255738A IL 255738 A IL255738 A IL 255738A IL 25573817 A IL25573817 A IL 25573817A IL 255738 A IL255738 A IL 255738A
Authority
IL
Israel
Prior art keywords
preparation
crystalline form
novel crystalline
lenvatinib mesylate
lenvatinib
Prior art date
Application number
IL255738A
Other languages
English (en)
Hebrew (he)
Original Assignee
Crystal Pharmatech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crystal Pharmatech Co Ltd filed Critical Crystal Pharmatech Co Ltd
Publication of IL255738A publication Critical patent/IL255738A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/02—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
    • C07C255/03—Mononitriles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
IL255738A 2015-05-21 2017-11-19 A new crystalline form of lenbatinib mesylate and a process for its preparation IL255738A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510263300 2015-05-21
PCT/CN2016/085360 WO2016184436A1 (zh) 2015-05-21 2016-06-08 乐伐替尼甲磺酸盐的新晶型及其制备方法

Publications (1)

Publication Number Publication Date
IL255738A true IL255738A (en) 2018-01-31

Family

ID=57319484

Family Applications (1)

Application Number Title Priority Date Filing Date
IL255738A IL255738A (en) 2015-05-21 2017-11-19 A new crystalline form of lenbatinib mesylate and a process for its preparation

Country Status (7)

Country Link
US (1) US10246418B2 (enExample)
EP (1) EP3287444A4 (enExample)
JP (1) JP2018520205A (enExample)
CN (2) CN113527203B (enExample)
IL (1) IL255738A (enExample)
MX (1) MX2017014799A (enExample)
WO (1) WO2016184436A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107075051B (zh) 2014-09-30 2019-09-03 株式会社Lg化学 嵌段共聚物
US10562855B2 (en) * 2016-06-08 2020-02-18 Crystal Pharmatech Co., Ltd. Crystalline form of lenvantinib mesylate and process of preparation thereof
BR112019013581A2 (pt) * 2016-12-29 2020-01-07 Dr. Reddy’S Laboratories Limited Formas no estado sólido de mesilato de lenvatinibe
CN110494423B (zh) * 2017-04-25 2022-04-26 苏州科睿思制药有限公司 乐伐替尼甲磺酸盐的新晶型及其制备方法
WO2019111283A1 (en) * 2017-12-09 2019-06-13 Msn Laboratories Private Limited, R&D Center Novel polymorphs of 4-[3-chloro-4-(n'-cyclopropyl ureido)phenoxy]-7-methoxyquinoline-6-carboxamide, its salts and process for the preparation thereof
CN109988112A (zh) * 2017-12-29 2019-07-09 四川科伦药物研究院有限公司 仑伐替尼甲磺酸盐的晶型及其制备方法
WO2019228485A1 (zh) * 2018-06-01 2019-12-05 成都苑东生物制药股份有限公司 一种甲磺酸乐伐替尼新晶型及其制备方法
CN110818634B (zh) * 2018-08-13 2021-11-30 上海新礼泰药业有限公司 甲磺酸乐伐替尼的精制方法
EP3620453A1 (en) 2018-09-07 2020-03-11 Indena S.p.A. New crystal form of lenvatinib
CN111574359A (zh) * 2019-02-19 2020-08-25 愈磐生物科技（苏州）有限公司 乐伐替尼-没食子酸共晶晶型及其应用
CN111689897B (zh) * 2019-03-13 2024-02-06 齐鲁制药有限公司 一种高纯度甲磺酸乐伐替尼晶型c的制备方法
CN109867626A (zh) * 2019-04-18 2019-06-11 安礼特（上海）医药科技有限公司 一种甲磺酸仑伐替尼多晶型物及其制备方法
CN110229103A (zh) * 2019-06-27 2019-09-13 尚科生物医药（上海）有限公司 一种乐伐替尼甲磺酸盐晶型b的制备方法
CN112174886A (zh) * 2019-07-02 2021-01-05 成都苑东生物制药股份有限公司 一种甲磺酸乐伐替尼晶型x的制备方法
WO2021007189A1 (en) * 2019-07-08 2021-01-14 Rezolute, Inc. Crystalline forms of plasma kallikrein inhibitors
CN110563644A (zh) * 2019-10-30 2019-12-13 北京赛思源生物医药技术有限公司 一种仑伐替尼甲磺酸盐的新晶型
US11059787B2 (en) 2019-11-12 2021-07-13 Shenzhen Bolan Pharmaceutical Co., Ltd Crystalline form of lenvatinib mesylate and methods thereof
CN117945999B (zh) * 2020-01-19 2025-08-22 重庆医药工业研究院有限责任公司 一种氟伐替尼或甲磺酸盐的晶型及其制备方法
WO2021213453A1 (zh) * 2020-04-24 2021-10-28 成都苑东生物制药股份有限公司 一种甲磺酸仑伐替尼晶型xi及其制备方法
CN112939859B (zh) * 2021-02-03 2022-03-11 南京方生和医药科技有限公司 甲磺酸仑伐替尼m晶型的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
SI1698623T1 (sl) 2003-12-25 2015-07-31 Eisai R&D Management Co., Ltd. Kristal soli 4-(3-kloro -4-(ciklopropilaminokarbonil)amino-fenoksi)-7- metoksi-6-kinolinkarboksamida ali njihov solvat in postopek njune proizvodnje
JP4834553B2 (ja) * 2004-09-17 2011-12-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物
CA2606719C (en) * 2005-06-23 2010-08-10 Eisai R & D Management Co., Ltd. Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for producing the same
ME02359B (me) * 2009-08-19 2016-06-20 Eisai R&D Man Co Ltd Farmaceutska kompozicija koja sadrži derivate hinolina

Also Published As

Publication number Publication date
CN113527203B (zh) 2023-07-25
CN113527203A (zh) 2021-10-22
US20180155291A1 (en) 2018-06-07
US10246418B2 (en) 2019-04-02
EP3287444A1 (en) 2018-02-28
CN107848979A (zh) 2018-03-27
MX2017014799A (es) 2023-02-23
EP3287444A4 (en) 2018-09-12
WO2016184436A1 (zh) 2016-11-24
JP2018520205A (ja) 2018-07-26

Similar Documents

Publication Publication Date Title
IL255738A (en) A new crystalline form of lenbatinib mesylate and a process for its preparation
IL253360A0 (en) New crystalline forms of neratinib malate and a process for their preparation
SG10201913200XA (en) Crystalline form of lorlatinib free base
IL256381A (en) Cryo-deposit preparations and methods for their preparation
PL4001481T3 (pl) Odzież i sposób jej wytwarzania
IL274142A (en) A process for the preparation of sanicriviroc and related analogs
PL3327012T3 (pl) Krystaliczne postacie bilastyny i sposoby ich wytwarzania
SG11201803284YA (en) Novel method of use and compositions
GB2555748B (en) Novel form of isoxadifen-ethyl, process for preparation and use thereof
SG11201803241YA (en) Innovative preparation and crystallization of iosimenol
IL254597A0 (en) Crystalline form of ahu377, method for its preparation and use
GB2565419B (en) Process for preparing novel crystalline form of mesosulfuron-methyl and use thereof
GB2559718B (en) Novel crystalline form of tribenuron-methyl, process for preparation and use thereof
IL253077A0 (en) Process and intermediates for the preparation of Fermpanel
HUP1500647A2 (en) Intermediate of baricitinib and process for its preparation
GB201509023D0 (en) Compositions and methods of production thereof
GB201721201D0 (en) Process for preparing novel crystalline form of iodosulfuron-methyl-sodium and use
GB2561750B (en) Novel crystalline form of thifensulfuron-methyl, process for preparation and use thereof
GB201720181D0 (en) Process for preparing novel crystalline form of metsulfuron-methyl and use thereof
GB201519465D0 (en) Composition and methods of production therof
GB201510576D0 (en) Implants and methods of forming thereof
GB201518221D0 (en) Novel material and process of manufacture